Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?
- PMID: 24419257
- DOI: 10.1038/nrcardio.2013.220
Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?
Abstract
The VISTA-16 trial of varespladib, a secretory phospholipase A2 (sPLA2) inhibitor, in patients with an acute coronary syndrome was terminated prematurely owing to futility and a signal towards harm. Despite these discouraging results, therapies that target inflammation to modify pathways in atherogenesis remain an area of active investigation.
Comment on
-
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.JAMA. 2014 Jan 15;311(3):252-62. doi: 10.1001/jama.2013.282836. JAMA. 2014. PMID: 24247616 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials